晚期非小细胞肺癌免疫治疗最新进展  

Recent progress in immunotherapy of advanced non-small cell lung cancer

作　　者：蔚晓勇 李晓凤[2] 张志宇 赵晓飞[2] 史婉婷 YU Xiao-yong;LI Xiao-feng;ZHANG Zhi-yu(Department of Medical Oncology,Bayannur Hospital,Bayannur 015000,China)

机构地区：[1]巴彦淖尔市医院肿瘤内科,015000 [2]包头市肿瘤医院胸部肿瘤科,014000 [3]包头医学院(研究生学院),014000

出　　处：《中国实用医药》2022年第14期181-184,共4页China Practical Medicine

基　　金：吴阶平医学基金会临床科研专项资助基金课题立项项目(项目编号:320.6750.19094-37)项目名称:PD-1联合多西他赛二线治疗晚期非小细胞肺癌的临床研究。

摘　　要：近年来,非小细胞肺癌(NSCLC)患者应用以免疫检查点抑制剂为代表的免疫治疗后生存情况不仅得到明显好转,且改变了非小细胞肺癌的治疗模式。本文以免疫治疗联合化疗的机制、免疫治疗有效性相关因素以及免疫相关预测因素为主进行综述,旨在为提高患者生存时间和质量、改善患者预后提供更多的理论依据。In recent years,immunotherapy represented by immune checkpoint inhibitors has not only significantly improved the survival of patients with advanced non-small cell lung cancer(NSCLC)but also changed the treatment mode of NSCLC.This paper reviews the mechanism of immunotherapy combined with chemotherapy,factors related to the effectiveness of immunotherapy and immune-related predictors,in order to provide more theoretical basis for improving the survival time and quality of patients and improving the prognosis of patients.

关 键 词：晚期非小细胞肺癌 免疫检查点抑制剂 免疫治疗有效性 肿瘤相关生物标记物 

分 类 号：R734.2[医药卫生—肿瘤]